Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Enlivex ( (ENLV) ).
Enlivex Therapeutics Ltd. announced that it will hold its Annual General Meeting of Shareholders on November 10, 2025, at its offices in Ness Ziona, Israel. The meeting will address several key proposals, including the election of board members, an increase in authorized share capital, and the re-appointment of the company’s independent registered public accounting firm. Shareholders will also have the opportunity to discuss the company’s financial statements for the year ended December 31, 2024. This meeting is significant for stakeholders as it involves decisions that could impact the company’s governance and financial strategy.
The most recent analyst rating on (ENLV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
Spark’s Take on ENLV Stock
According to Spark, TipRanks’ AI Analyst, ENLV is a Underperform.
Enlivex’s financial challenges, characterized by no revenue and ongoing cash burn, significantly impact its stock score. Technical indicators show neutral momentum, but the negative valuation metrics reflect ongoing financial difficulties. The absence of positive corporate events or earnings call data limits the potential for a higher score.
To see Spark’s full report on ENLV stock, click here.
More about Enlivex
Enlivex Therapeutics Ltd. is a company based in Israel, operating in the biotechnology industry. The company focuses on developing innovative therapies for life-threatening immune-related diseases.
Average Trading Volume: 542,766
Technical Sentiment Signal: Strong Sell
Current Market Cap: $24.93M
Find detailed analytics on ENLV stock on TipRanks’ Stock Analysis page.